Zydus Cadila has received final approval from the U.S. FDA to market Nelarabine injection 250MG/50ML in the United States (US RLD: Arranon). Zydus Pharmaceuticals USA was granted a Competitive Generic Therapy (CGT) designation for Nelarabine Injection, 250 mg/50 mL (5 mg/mL), Single-Dose Vial.

Zydus is the "first approved applicant" for Nelarabine Injection, 250 mg/50 mL (5 mg/mL), Single-Dose Vial, as defined in section 505(j)(5)(B)(v)(III) of the FD&C Act. Therefore, with this approval, Zydus is eligible for 180 days of CGT exclusivity for Nelarabine injection, 250 mg/50 mL (5 mg/mL), single-dose vial, under section 505(j)(5)(B)(v) of the FD&C Act.

Nelarabine Injection had annual sales of approximately US $ 34.5 million in the United States according to IQVIA data (September 2021). The drug is manufactured at the group's injection manufacturing facility, Alidac plant in Ahmedabad and shall be launched commercially within the US market immediately.

This medication is a chemotherapy drug and is used to treat certain types of leukaemia and lymphoma by slowing or stopping the growth of cancer cells. Nelarabine is in a class of medications called antimetabolites.

Speaking on the development, Dr. Sharvil Patel, Managing Director, Cadila Healthcare said, "This FDA approval of Nelarabine injection underlines our long-term commitment to patients of providing them access to affordable generics. This approval builds on our proven track record of successfully commercializing and gaining meaningful market share in complex generics products. We have created a diversified portfolio of more than 50 filed complex ANDAs and will continue to focus on complex generic products as we continue to explore opportunities to grow our US business."